SCHEMBL27373585

SCHEMBL27373585

Cc1cccc(Br)c1OCC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ ATM Q13315 1/20 0.43
▸ KMT2A Q03164 6/20 0.40
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ MEN1 O00255 5/20 0.39
▸ POLB P06746 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALPL P05186 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20898899 0.82 NLRP3 (0.50) L3MBTL1ATMKMT2AMEN1HTT
SCHEMBL20136944 0.80 ALOX5AP (0.40) L3MBTL1ATMKMT2ADDB1CRBN
SCHEMBL7105655 0.79 DDB1 (0.53) L3MBTL1KMT2ADDB1CRBNMEN1
SCHEMBL13665121 0.79 SSTR4 (0.47) L3MBTL1ATMKMT2ADDB1CRBN
SCHEMBL14277707 0.77 GRM4 (0.51) L3MBTL1KMT2ADDB1CRBNMEN1
SCHEMBL20398155 0.76 DDB1 (0.49) L3MBTL1KMT2ADDB1CRBNMEN1
SCHEMBL3193143 0.76 KMT2A (0.41) L3MBTL1ATMKMT2ADDB1CRBN
SCHEMBL7862085 0.75 NOTUM (0.53) ATMKMT2ADDB1CRBNMEN1
SCHEMBL21883674 0.74 PSEN1 (0.46) L3MBTL1KMT2ADDB1CRBNMEN1
SCHEMBL25629330 0.73 KMT2A (0.41) L3MBTL1ATMKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
EP-4562016-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 L3MBTL1 1574/4885ATM 1075/4885KMT2A 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback